Alvotech_logo.jpg
Alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma
July 11, 2024 04:45 ET | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að endurfjármögnun skulda félagsins væri nú lokið. Með því hefur félagið lækkað fjármagnskostnað og lengt lánstíma útistandandi skulda. Að endurfjármögnuninni...
Alvotech_logo.jpg
Alvotech Announces Closing of Private Debt Financing
July 11, 2024 04:45 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...
Alvotech kynnir jákv
Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva
July 02, 2024 09:00 ET | Alvotech
Jákvæðar niðurstöður rannsóknarinnar sýna sambærilega klíníska virkni AVT03 og samanburðarlyfsins Prolia (denosumab) í sjúklingum Endapunktur var einnig uppfylltur í tveimur klínískum rannsóknum þar...
Alvotech Announces P
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024 09:00 ET | Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech Announces P
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024 09:00 ET | Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech_logo.jpg
Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf
July 01, 2024 17:35 ET | Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gefið út nýja hluti í skiptum fyrir breytileg skuldabréf, sem upprunalega voru gefin út af Alvotech í nóvember og desember 2022 og voru með...
Alvotech_logo.jpg
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024 17:35 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated...
Picture1.png
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
July 01, 2024 08:00 ET | CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatm
Alvotech_logo.jpg
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET | Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech_logo.jpg
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET | Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...